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Abstract
Introduction: Hashimoto’s Encephalopathy is an unusual condition associated with Hashimoto’s
Thyroiditis. This immune-mediated, steroid-dependent entity was first described thirty years ago. In this
case report, we discuss the importance of considering this diagnosis in the evaluation of confusion.
Case presentation: The patient is a 55-year-old African-American woman residing in United
States, who was admitted to the hospital with a four-day history of mental status changes. Her past
medical history was significant for type II Diabetes Mellitus, Hypertension, and Hypothyroidism.
There was no reported seizure activity. The patient’s vital signs were stable on admission. On
examination, the patient was awake, alert, oriented to place and time. Her neurological examination
revealed agraphia and dyslexia. Her speech showed lack of fluency and hesitation. Her complete
blood count and electrolytes were within normal limits. The patient’s brain CT scan did not reveal
any significant findings. Her Magnetic Resonance Imaging only revealed mild chronic microangiopathy,
which caused by “small vessel disease.” Her Electroencephalogram did not reveal any finding
consistent with seizure activity. Cerebral spinal fluid analysis was likewise did not reveal a cause for
this patient’s acute onset of confusion. In contrast to the above negative finding, this patient’s Thyroid
stimulating hormone was discovered to be 15 UIU/ml. She was subsequently given 1000 mg of
intravenous Methylprednisolone daily for 3 days. This three-day course of high-dose, intravenous
steroids resulted complete resolution of the patient’s symptoms. She was then discharged on an
eleven-day course of oral prednisone 60 mg.
Conclusion: Hashimoto’s Encephalopathy should beconsidered in thedifferential diagnosis ofanacute
confusional state since it is responsive to steroid therapy and represents a readily reversible cause acute
mental status changes. Clues to this diagnosis include elevated antithyroid antibodies, abnormal Thyroid
stimulating hormone values, and exclusion of other causes of acute mental status changes.
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Hashimoto’s encephalopathy (HE) is a rare clinical
syndrome that has been associated with elevated anti
thyroid antibodies. As a result of confusion regarding any
association with hypothyroidism, HE is now more
frequently known by the name “Steroid Responsive
Autoimmune Thyroiditis (SREAT)”.
This immune-mediated, steroid-dependent entity was first
described in 1966 [1]. It is more commonly seen in
women. Since this condition can result in seizure activity
and requires treatment beyond simple hormone replace-
ment, it must be entertained inthe differential diagnosis of
mental status changes in a patient with hypothyroidism.
We present the case of one such patient who presented
with an acute confusional state due to Hashimoto’s
encephalopathy.
Case presentation
A 55-year-old African-American woman residing in United
States was admitted to the hospital with a four-day history
of mental status changes complicated by left-sided
weakness. Her family reported that she had been acting
strange, including exhibiting aggressive behavior towards
her niece. On interview, the patient reported that her
family members were trying to hurt her. This patient also
reported auditory hallucinations, stating, “fire alarms were
constantly going off in her house.” Her past medical
history was significant for type II diabetes mellitus,
hypertension, breast cancer and hypothyroidism. She did
not have any past psychiatric or seizure history. Review of
systems was only notable for the issues already discussed.
The patient’s vital signs were stable with a blood pressure
of 122/62 mm Hg, respiratory rate of 14 breaths per
minute, heart rate of 98 beats per minute and a
temperature of 36.4º centigrade. On examination, the
patient was awake, alert, and oriented only to her name.
Examination of heart, lungs and abdomen were within
normal limits. Thyroid examination was likewise within
normal limits. Her neurological examination revealed
disorientation to place and time, poor memory, agraphia,
dyslexia, and an unusual form of aphasia where the
patient was observed to be unable to read or write, but was
able to spell words on request. Her speech showed lack of
fluency and marked hesitation. Her pupils were equal and
reactive-to-light. Fundoscopic examination could not be
successfully performed due to the presence of bilateral
cataracts. Cranial nerve and sensory examination showed
no abnormalities. Muscle strength and deep tendon
reflexes were within normal limits.
Results of complete blood count testing were within
normal limits. Metabolic panel testing was notable for
serum glucose of 458 mg/dl. TSH levels were increased
to 15 UIU/ml. Microsomal antibodies was raised at
617 IU/ml. Vitamin B12 was normal with value of
258 pg/ml. The patient’s RPR was negative. Free T4 was
not done due to the patient’s refusal. Cerebral spinal fluid
analysis was within normal limits. Likewise, the patient’s
electroencephalogram did not show any seizure activity
or evidence of encephalopathy. Her magnetic resonance
imaging revealed mild, chronic microangiopathy.
The patient was subsequently given 1000 mg of intrave-
nous Methylprednisolone, repeated daily, for a total of
3 days. This three-day course of high-dose, intravenous
steroids resulted in resolution of the patient’s symptoms.
She was then discharged on an eleven-day course of oral
prednisone 60 mg, for a total of fourteen days of therapy.
She has subsequently been followed in a community clinic
in her home town. To date, no recurrence of symptoms has
been reported.
Discussion
Despite its eponym, Hashimoto’s Encephalopathy (HE)
[2] is only related to Hashimoto’s Thyroiditis by the
common presence of anti-thyroid antibodies. Clinical
manifestations most often consist of an acute to sub-acute
onset of confusion associated with an alteration of
consciousness, seizure activity, or myoclonus, and may
include hallucinations and delusions.
In reviewing the multitude of conditions that may lead to
progressive mental status changes in an elderly patient,
such conditions as metabolic derangements, autoimmune
conditions, paraneoplastic encephalopathy, infection,
psychiatric illness, and progressive neurologic conditions
must be considered. HE distinguishes itself through its
rapid deterioration in mental status, lack of specific
electrolyte or radiographic abnormalities, and specific
response to immunosuppressive and immunomodulating
agents. Although prion-related encephalopathies, such as
Creutzfeldt-Jakob Disease (CJD), are considered in the
differential diagnosis of HE, the rapid decline in mental
status seen in HE distinguishes it from CJD, which causes a
slower decline in functional status, and ultimately results
in death [3].
The exact etiology for this neurological state is not known.
As elevated immunoglobulin levels are usually seen in this
condition, an inflammatory state has been conjectured to
be pathologically responsible [4]. Given this condition’s
similarities to non-vasculitic, autoimmune, inflammatory
meningoencephalopathies, it has been suggested that this
condition’s name should be changed to “Steroid Respon-
sive Encephalopathy Associated with Autoimmune Thyr-
oiditis,” in order to better characterize what we know
about the pathophysiology of this condition [5]. Over the
last 40 years, the diagnosis of this condition has been
hindered by a lack of universally agreed upon diagnostic
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defined criteria have been delineated and include ence-
phalopathy with neuropsychiatric features, seizure activity
or focal neurologic deficits; presence of antithyroid
antibodies; euthyroid status or mild hypothyroidism; no
compelling evidence for a more likely etiology, and
reversal of symptoms with steroid administration [6].
Laboratory evaluation is critical to making this diagnosis
and will typically show an elevated serum level of anti-
thyroperoxidase antibody or anti-thyroglobulin antibody.
These antibodies, though frequently present, are not felt to
be pathogenic, but simply a marker for an underlying
disease, possibly an inflammatory meningoencephalopa-
thy. Since cases of HE have been described in patients with
a background metabolic milieu in the euthyroid, hyper-
throid, and hypothyroid range, HE is felt not be related to
thyroid disease. Cerebrospinal fluid analysis (CSF) is
abnormal in approximately 80 percent of patients, usually
revealing an elevated CSF protein levels. Other CSF
findings include lymphocytic pleocytosis as well as the
presence of oligoclonal bands and immune complexes
[7,8]. In the case of our patient, no such abnormalities
were discerned. Nonspecific electroencephalographic
(EEG) abnormalities are seen in 90 to 98 percent of
patients with the most common finding being nonspecific
slowing of background activity [9]. Again, in the case of
our index patient, no diagnostic abnormalities were
found. Magnetic resonance imaging in patients with
Hashimoto’s encephalopathy is usually normal. In some
patients, particularly those with concomitant cerebral
atrophy, T2 signal abnormalities of white matter are
noted.
Recognizing that the acute confusional state seen in HE is
not related to thyroid status and may exacerbate any
mental status changes associated with severe hyperthyr-
oidism or hypothyroidism, correction or near correction of
thyroid function abnormalities is frequently required for
the diagnosis of this condition. This condition must be
considered separate from confusion related to thyroid
disease since the addition of immunomodulating agents
will be required for its specific treatment. Despite the fact
that corticosteroids are widely accepted as the standard
treatment for HE, there is no consensus on indications for
usage or pharmacologic dosing [10]. There appears to be
not consensus on the optimal dose or duration of steroid
therapy. One approach advocates a dose of oral Predni-
sone ranging from 50 to 150 mg each day. Another
approach recommends the use of high dose, intravenous
Methylprednisone, although there are no studies compar-
ing outcomes using the different administration and
dosing strategies. In the case series described by Castillo
et al., seventeen of twenty patients received a five-day
course of Methylprednisolone 1 gram each day for five
days followed by oral steroids in six of these patients. The
three remaining patients received between ten to thirty
days of oral Prednisone, ranging in doses from 60-100 mg.
No difference was mentioned in outcomes, and eight of
the total twenty patients (40%) followed, were able to
discontinue steroid therapy without a relapse insymptoms
[6].
In the case of patients who cannot tolerate corticosteroids
or who do not respond to corticosteroids, agents such
as Azathioprine and Cyclophosphamide have been
employed. In other refractory cases, clinical improvement
has been documented using either intravenous immuno-
globulin or plasmapheresis [11].
Conclusion
Hashimoto’s encephalopathy is an uncommon complica-
tion of thyroid disease, which is readily treatable with
conventional modes of pharmacotherapy. As our case and
the available literature show, a rapid reversible in the
patient’s confusion and neurologic debility can be affected
after the initiation of therapy. Furthermore, the literature
maintains that this disease entity distinguishes itself from
confusional states associated with thyroid hormone
derangements by its response to steroids or other therapies
for autoimmune disease. Our patient exhibited such a
response. Thus, although this condition may be con-
sidered rare, its sensitivity to medical intervention
necessitates that we consider it in our differential diagnosis
for acute, and possibly long-term, confusional states; if we
do not, we will miss a readily reversible cause for mental
status changes.
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